RESUMO
A clinical study was made into the abilities of nicarbazin and monensin and a nicarbazin + monensin combination to control Eimeria acervulina, E. maxima, and E. tenella in chickens. When included in the feed, at concentrations of 40â ppm nicarbazin or 40â ppm monensin, these products showed partial efficacy evaluated by daily weight gain (DWG) but no activity judged by daily feed intake (DFI) or feed conversion ratio (FCR). By contrast, the combination of 40â ppm nicarbazin + 40â ppm monensin provided complete control of infection judged by greater DWG and DFI, and lower FCR. Monensin at a concentration of 40â ppm was ineffective in preventing lesions caused by all three species. Nicarbazin at a concentration of 40â ppm was unable to suppress lesions of E. acervulina and E. maxima but was able to suppress lesions caused by E. tenella. Nicarbazin 40â ppm + monensin 40â ppm suppressed lesions of all three species. RESEARCH HIGHLIGHTS Nicarbazin or monensin at 40 ppm gave only partial control of Eimeria spp. A combination of 40 ppm nicarbazin + 40 ppm monensin controlled DWG, DFI and FCR. Nicarbazin or monensin at 40 ppm did not suppress all Eimeria spp. lesions. Nicarbazin 40 ppm + monensin 40 ppm suppressed lesions of all three species.
Assuntos
Coccidiose/veterinária , Coccidiostáticos/administração & dosagem , Eimeria/efeitos dos fármacos , Monensin/administração & dosagem , Nicarbazina/administração & dosagem , Doenças das Aves Domésticas/tratamento farmacológico , Animais , Coccidiose/tratamento farmacológico , Coccidiose/parasitologia , Sinergismo Farmacológico , Eimeria/genética , Masculino , Doenças das Aves Domésticas/virologiaRESUMO
Medicinal plants containing complex mixtures of several compounds with various potential beneficial biological effects are attractive treatment interventions for a complex multi-faceted disease like diabetes. In this study, compounds identified from African medicinal plants were evaluated for their potential anti-diabetic activity. A total of 867 compounds identified from over 300 medicinal plants were screened in silico with the DIA-DB web server (http://bio-hpc.eu/software/dia-db/) against 17 known anti-diabetic drug targets. Four hundred and thirty compounds were identified as potential inhibitors, with 184 plants being identified as the sources of these compounds. The plants Argemone ochroleuca, Clivia miniata, Crinum bulbispermum, Danais fragans, Dioscorea dregeana, Dodonaea angustifolia, Eucomis autumnalis, Gnidia kraussiana, Melianthus comosus, Mondia whitei, Pelargonium sidoides, Typha capensis, Vinca minor, Voacanga Africana, and Xysmalobium undulatum were identified as new sources rich in compounds with a potential anti-diabetic activity. The major targets identified for the natural compounds were aldose reductase, hydroxysteroid 11-beta dehydrogenase 1, dipeptidyl peptidase 4, and peroxisome proliferator-activated receptor delta. More than 30% of the compounds had five or more potential targets. A hierarchical clustering analysis coupled with a maximum common substructure analysis revealed the importance of the flavonoid backbone for predicting potential activity against aldose reductase and hydroxysteroid 11-beta dehydrogenase 1. Filtering with physiochemical and the absorption, distribution, metabolism, excretion and toxicity (ADMET) descriptors identified 28 compounds with favorable ADMET properties. The six compounds-crotofoline A, erythraline, henningsiine, nauclefidine, vinburnine, and voaphylline-were identified as novel potential multi-targeted anti-diabetic compounds, with favorable ADMET properties for further drug development.
Assuntos
Hipoglicemiantes/análise , Hipoglicemiantes/farmacologia , Internet , Plantas Medicinais/química , Interface Usuário-Computador , Disponibilidade Biológica , Hipoglicemiantes/química , Simulação de Acoplamento MolecularRESUMO
A renormalization group flow of Hamiltonians for two-dimensional classical partition functions is constructed using tensor networks. Similar to tensor network renormalization [G. Evenbly and G. Vidal, Phys. Rev. Lett. 115, 180405 (2015)PRLTAO0031-900710.1103/PhysRevLett.115.180405; S. Yang, Z.-C. Gu, and X.-G. Wen, Phys. Rev. Lett. 118, 110504 (2017)PRLTAO0031-900710.1103/PhysRevLett.118.110504], we obtain approximate fixed point tensor networks at criticality. Our formalism, however, preserves positivity of the tensors at every step and hence yields an interpretation in terms of Hamiltonian flows. We emphasize that the key difference between tensor network approaches and Kadanoff's spin blocking method can be understood in terms of a change of the local basis at every decimation step, a property which is crucial to overcome the area law of mutual information. We derive algebraic relations for fixed point tensors, calculate critical exponents, and benchmark our method on the Ising model and the six-vertex model.
RESUMO
In order to analyze the effect of vaccination in a population with the presence of viruses, a variation of the SIR (Susceptible-Infected-Removed) model is proposed taking into account social distancing and the effect of the vaccine. The equilibrium points of the proposed model are calculated and the stability analysis of the system is carried out. For the proposed model, disease-free equilibrium point and endemic equilibrium point are found and the conditions of existence are discussed. For the disease-free equilibrium point the bifurcation conditions are derived and simulations show that reducing the vaccination effort can lead the disease-free equilibrium to the endemic equilibrium. From the theoretical analysis, a minimum value of effort is obtained to guarantee a disease-free equilibrium point. Simulations were carried out from the value obtained from Rv to validate the theoretical results.
RESUMO
Necrotic enteritis poses an important health risk to broilers. The ionophore anticoccidials lasalocid, salinomycin, maduramicin, narasin and a combination of narasin and nicarbazin were tested in feed for their prophylactic effect on the incidence of necrotic enteritis in a subclinical experimental infection model that uses coccidia as a predisposing factor. In addition, drinking water medication with the antibiotics amoxicillin, tylosin and lincomycin was evaluated as curative treatment in the same experimental model. The minimal inhibitory concentrations (MICs) of all antibiotics and anticoccidials were determined in vitro against 51 Clostridium perfringens strains isolated from broilers. The strains examined appeared uniformly susceptible to lasalocid, maduramicin, narasin, salinomycin, amoxicillin and tylosin, whereas an extended frequency distribution range of MICs for lincomycin was seen, indicating acquired resistance in 36 isolates in the higher range of MICs. Nicarbazin did not inhibit the in vitro growth of the C. perfringens strains even at a concentration of 128 microg/ml. Supplementation of the diet from day 1 onwards with lasalocid, salinomycin, narasin or maduramicin led to a reduction in birds with necrotic enteritis lesions as compared with the non-medicated infected control group. A combination product of narasin and nicarbazin had no significant protective effect. Treatment with amoxicillin, lincomycin and tylosin completely stopped the development of necrotic lesions.
Assuntos
Antibacterianos/uso terapêutico , Coccidiose/veterinária , Coccidiostáticos/uso terapêutico , Enterite/veterinária , Doenças das Aves Domésticas/prevenção & controle , Ração Animal , Animais , Galinhas , Infecções por Clostridium/tratamento farmacológico , Infecções por Clostridium/veterinária , Clostridium perfringens/efeitos dos fármacos , Coccídios , Coccidiose/complicações , Coccidiose/epidemiologia , Modelos Animais de Doenças , Farmacorresistência Bacteriana , Enterite/tratamento farmacológico , Enterite/etiologia , Enterite/microbiologia , Enterite/patologia , Enterite/prevenção & controle , Aditivos Alimentares/uso terapêutico , Testes de Sensibilidade Microbiana , Necrose , Doenças das Aves Domésticas/etiologiaRESUMO
Natural killer (NK) cells are large granular lymphocytes that constitutively express functional IL-2 receptors. We have shown that recombinant human IL-15 uses the IL-2 receptor to activate human NK cells and can synergize with recombinant human IL-12 to stimulate NK cell production of IFN-gamma in vitro. IFN-gamma production by NK cells is critical in the prevention of overwhelming infection by obligate intracellular microbial pathogens in several experimental animal models. Herein, we demonstrate that human monocytes produce IL-15 protein within 5 h of activation with LPS. Using an IL-15-neutralizing antiserum in a coculture of LPS-activated monocytes and NK cells, we demonstrate that monocyte-derived IL-15 is critical for optimal NK cell production of IFN-gamma. Endogenous IL-15 activates NK cells through the IL-2 receptor, and with endogenous IL-12, regulates NK cell IFN-gamma after monocyte activation by LPS. These in vitro studies are the first to characterize a function for endogenous IL-15, and as such, suggest an important role for IL-15 during the innate immune response. IL-15 may be an important ligand for the NK cell IL-2 receptor in vivo.
Assuntos
Interferon gama/biossíntese , Interleucinas/biossíntese , Interleucinas/farmacologia , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Monócitos/imunologia , Receptores de Interleucina-2/fisiologia , Animais , Anticorpos Monoclonais , Western Blotting , Células Cultivadas , Técnicas de Cocultura , Sinergismo Farmacológico , Ensaio de Imunoadsorção Enzimática , Escherichia coli , Humanos , Imuno-Histoquímica , Interleucina-12/farmacologia , Interleucina-15 , Interleucinas/análise , Células Matadoras Naturais/efeitos dos fármacos , Cinética , Lipopolissacarídeos/farmacologia , Monócitos/efeitos dos fármacos , Proteínas Recombinantes/farmacologiaRESUMO
To obtain better insights into the possible exchange of resistance genes between human and animal streptococci, the sequences of the erm (B) genes of streptococcal isolates from humans, pigs, pork carcasses, chickens, and calves were compared. Identical erm (B) gene sequences were present in strains from humans, pigs, pork carcasses, and calves. During in vitro mating experiments, the erm (B) gene was exchanged between porcine Streptococcus suis and human S. pneumoniae, S. pyogenes, and S. oralis strains. The presence of different tetracycline resistance genes and the int Tn 1545 gene was determined in animal streptococci carrying the erm (B) gene. Although tet(M) and int Tn 1545 genes were detected in 24% of the porcine and pork carcass streptococcal strains, the tet(O) gene was the predominant tetracycline resistance gene in these strains (81%). The latter gene was co-transferred with the erm (B) gene from porcine S. suis strains to human streptococci in the mating experiments. These results show that, identical erm (B) gene sequences were present in animal and human streptococci and that transfer of the erm (B) gene from porcine S. suis to human streptococci and vice versa is possible, but probably occurs at a low frequency.
Assuntos
Proteínas de Bactérias/genética , Portador Sadio/microbiologia , Eritromicina/farmacologia , Metiltransferases/genética , Infecções Estreptocócicas/veterinária , Streptococcus/efeitos dos fármacos , Animais , Animais Domésticos , Portador Sadio/epidemiologia , DNA Bacteriano/análise , Farmacorresistência Bacteriana , Humanos , Infecções Estreptocócicas/transmissão , Streptococcus/classificação , Streptococcus/genéticaRESUMO
Previous studies have shown that the systemic injection of tryptamine stimulates locomotion in rats and that the nucleus accumbens, a region involved in locomotion, contains the largest concentrations of binding sites for tryptamine in the brain of the rat. The present study examined the behavioral and neurochemical effects of bilateral injections into the accumbens of a deuterated analog of tryptamine, a,a-[2H]tryptamine. Injections of 25 micrograms a,a-[2H]tryptamine increased movements in rats at 25-70 min after injection and increased vertical (rearing) activity at 25-40 min. Injections of 50 micrograms of a,a-[2H]tryptamine produced a transient suppression of movement and vertical activity at 5-15 min, followed by increases in these activities at 40-65 min after injection that were comparable to the increases elicited by 10 micrograms of d-amphetamine. At 30 min after the injection of 50 micrograms a,a-[2H]tryptamine the concentration of dopamine in the nucleus accumbens was increased by 87%, and was preceded by a transient decrease in the level of the metabolite of dopamine homovanillic acid. The levels of 5-hydroxytryptamine and its major metabolite, 5-hydroxyindoleacetic acid in the nucleus accumbens were not changed. Thus, a,a-[2H]tryptamine may interact with tryptamine receptors in the nucleus accumbens to modulate locomotor behavior through mesolimbic dopamine neurons.
Assuntos
Aminas Biogênicas/metabolismo , Encéfalo/metabolismo , Atividade Motora/efeitos dos fármacos , Triptaminas/farmacologia , Animais , Encéfalo/efeitos dos fármacos , Deutério , Dextroanfetamina/farmacologia , Injeções , Masculino , Nialamida/farmacologia , Núcleo Accumbens , Pargilina/farmacologia , Ratos , Ratos Endogâmicos , Triptaminas/administração & dosagemRESUMO
The effects of apomorphine and the putative dopamine autoreceptor agonist, CGS 15855A, were evaluated in several functional assays that are modulated by pre- or post-synaptic D2 receptors. These included release of prolactin in vivo and in vitro from cultured lactotrophs; levels of dihydroxyphenylacetic acid (DOPAC) in the striatum; levels of acetylcholine (ACh); in the striatum and concentrations of cyclic guanosine monophosphate (cyclic GMP) in the cerebellum. The secretion of prolactin was inhibited by CGS 15855A in vitro and in vivo and which also decreased the levels of DOPAC in the striatum at doses 5-25 times less than those required to increase ACh in the striatum and levels of cGMP in the cerebellum. In contrast, apomorphine possessed a dose-ratio between 1.5 and 8.6 for these assay systems. These data suggest that CGS 15855A is a selective dopamine autoreceptor agonist which preferentially stimulates D2 receptors on lactotrophs and dopaminergic neurons as compared to D2 receptors on cholinergic interneurons in the striatum.
Assuntos
Benzopiranos/farmacologia , Corpo Estriado/efeitos dos fármacos , Dopamina/metabolismo , Prolactina/metabolismo , Receptores Dopaminérgicos/efeitos dos fármacos , Animais , Apomorfina/farmacologia , Células Cultivadas , Corpo Estriado/metabolismo , Masculino , Hipófise/efeitos dos fármacos , Hipófise/metabolismo , Ratos , Ratos Endogâmicos , Receptores de Dopamina D2RESUMO
Intracerebroventricular injection of beta-endorphin stimulated the metabolism of dopamine in a dose-dependent, opiate antagonist-reversible manner. Local injections into the nucleus accumbens also caused similar increases, indicating that the actions of this peptide on mesolimbic dopaminergic projections were occurring at opioid receptor sites within the nucleus accumbens. Tolerance experiments suggested that epsilon opioid receptors may be involved in mediating these effects in the n. accumbens, unlike in the striatum.
Assuntos
Ventrículos Cerebrais/fisiologia , Corpo Estriado/metabolismo , Dopamina/metabolismo , Núcleo Accumbens/fisiologia , Núcleos Septais/fisiologia , beta-Endorfina/farmacologia , Ácido 3,4-Di-Hidroxifenilacético/metabolismo , Animais , Ventrículos Cerebrais/efeitos dos fármacos , Corpo Estriado/efeitos dos fármacos , Encefalina Leucina/análogos & derivados , Encefalina Leucina/farmacologia , Leucina Encefalina-2-Alanina , Ácido Homovanílico/metabolismo , Injeções Intraventriculares , Cinética , Masculino , Morfina/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Ratos , Ratos Endogâmicos , Valores de Referência , beta-Endorfina/administração & dosagemRESUMO
A new method has been developed to measure simultaneously the turnover rates of glutamate and GABA in individual areas of the brain of the rat. Rats received a constant infusion of [13C6]glucose, such that the flux of this stable isotope label through the pools of glucose, glutamate and GABA in the central nervous system (CNS) could be monitored by gas chromatography-mass fragmentography. The ratios of glucose/GABA and glucose/glutamate labelling were then used to calculate the fractional rate constants for GABA and glutamate, respectively. Using this approach, baclofen (20 mg/kg) decreased the turnover rates of both glutamate and GABA in the cerebellum, prefrontal cortex, striatum and hippocampus of the rat. In contrast, only the turnover of GABA was decreased in the septum and superior colliculus. Muscimol decreased the turnover rates of both amino acids in all regions of the brain examined. These data, therefore, provide in vivo support for the results of previous in vitro studies which indicated that cortical glutamatergic nerve endings and/or cell bodies possess inhibitory GABAB receptors. The present data further suggest that not all glutamatergic projections possess these receptors.
Assuntos
Encéfalo/metabolismo , Glucose/farmacologia , Glutamatos/metabolismo , Ácido gama-Aminobutírico/metabolismo , Aminoácidos/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Glucose/administração & dosagem , Infusões Intravenosas , Masculino , Ratos , Ratos EndogâmicosRESUMO
A new series of arylpiperazide derivatives of 1-naphthylpiperazine of general formula 4 has been prepared and evaluated as 5-HT1B antagonists. Binding experiments at cloned human 5-HT1A, 5-HT1B, and 5-HT1D receptors show that these derivatives are potent and selective ligands for 5-HT1B/1D subtypes with increased binding selectivity versus the 5-HT1A receptor when compared to 1-naphthylpiperazine (1-NP). Studies of inhibition of the forskolin-stimulated cAMP formation mediated by the human 5-HT1B receptor demonstrate that the nature of the arylpiperazide substituent modulates the intrinsic activity of these 1-NP derivatives. Among them, 2-[[8-(4-methylpiperazin-1-yl)naphthalen-2-yl]oxy] -1-(4-o-tolylpiperazin-1-yl)ethanone (4a) was identified as a potent neutral 5-HT1B antagonist able to antagonize the inhibition of 5-HT release induced by 5-CT (5-carbamoyltryptamine) in guinea pig hypothalamus slices. Moreover, 4a was found to potently antagonize the hypothermia induced by a selective 5-HT1B/1D agonist in vivo in the guinea pig following oral administration (ED50 = 0.13 mg/kg).
Assuntos
Piperazinas/síntese química , Piperazinas/farmacologia , Receptores de Serotonina/efeitos dos fármacos , Antagonistas da Serotonina/síntese química , Antagonistas da Serotonina/farmacologia , Agonistas do Receptor de Serotonina/síntese química , Agonistas do Receptor de Serotonina/farmacologia , Animais , Células CHO/metabolismo , Células CHO/ultraestrutura , Células COS/metabolismo , Células COS/ultraestrutura , Cricetinae , Desenho de Fármacos , Cobaias , Células HeLa , Humanos , Cinética , Piperazinas/metabolismo , Ratos , Receptor 5-HT1B de Serotonina , Receptores de Serotonina/metabolismo , Antagonistas da Serotonina/metabolismo , Agonistas do Receptor de Serotonina/metabolismoRESUMO
The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2, 3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.
Assuntos
Antagonistas Adrenérgicos alfa/síntese química , Dioxanos/síntese química , Imidazóis/síntese química , Receptores Adrenérgicos alfa 2/efeitos dos fármacos , Agonistas alfa-Adrenérgicos , Antagonistas Adrenérgicos alfa/química , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Córtex Cerebral/metabolismo , Corpo Estriado/metabolismo , Dioxanos/química , Dioxanos/metabolismo , Dioxanos/farmacologia , Guanabenzo , Hipotermia/induzido quimicamente , Hipotermia/tratamento farmacológico , Imidazóis/química , Imidazóis/metabolismo , Imidazóis/farmacologia , Técnicas In Vitro , Masculino , Membranas , Camundongos , Neuroglia/metabolismo , Ratos , Receptores Adrenérgicos alfa 1/efeitos dos fármacos , Receptores Adrenérgicos alfa 1/metabolismo , Receptores de Dopamina D2/efeitos dos fármacos , Receptores de Dopamina D2/metabolismo , Relação Estrutura-AtividadeRESUMO
A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents such as adamantylmethyl at N-1 and resolution of the racemic ureas resulted in our lead compound GV150013.
Assuntos
Ansiolíticos/síntese química , Benzodiazepinas/síntese química , Receptores da Colecistocinina/antagonistas & inibidores , Animais , Ansiolíticos/química , Ansiolíticos/farmacologia , Benzodiazepinas/química , Benzodiazepinas/farmacologia , Callithrix , Córtex Cerebral/metabolismo , Cristalografia por Raios X , Cobaias , Células HeLa , Humanos , Técnicas In Vitro , Membranas , Camundongos , Modelos Moleculares , Pâncreas/metabolismo , Ensaio Radioligante , Ratos , Receptor de Colecistocinina A , Receptor de Colecistocinina B , Receptores da Colecistocinina/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Acetylcholine release in the rat cortex in vivo has been shown to be modulated by alpha2-adrenoceptor ligands. We have previously reported that the systemic administration of selective alpha2-antagonists including (+)-efaroxan increase, while alpha2-adrenoceptor agonists such as UK-14304 reduce the release of acetylcholine in the medial prefrontal cortex of conscious rats as measured by microdialysis. To evaluate the extent to which noradrenergic afferent inputs are required for the expression of these different effects, the present study examined the drug-induced changes in cortical acetylcholine release in rats which had undergone prior noradrenergic deafferentation. Rats were pretreated with the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (40 mg/kg, i.p.), which after three days had reduced noradrenaline levels in the medial prefrontal cortex by 84%. At that time, slices of cortex were incubated with [3H]choline, superfused and stimulated by consecutive exposures to increasing concentrations of K+. In N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine pretreated tissue, the [3H] outflows evoked by 20, 35 and 45 mM K+ were lower by 12%, 22% and 43%, respectively, in comparison to slices prepared from vehicle-pretreated control animals. For in vivo microdialysis experiments, rats were pretreated as above with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine, or prepared seven to eight days in advance with bilateral 6-hydroxydopamine lesions of the locus coeruleus. Neither of these lesioning procedures significantly affected the basal outflow of endogenous acetylcholine in the cortex. In control rats, cortical acetylcholine outflow was increased by up to 300% of baseline values by (+)-efaroxan (0.63 mg/kg, i.p.), and was reduced to 21% of baseline by UK-14304 (2.5 mg/kg, i.p.), confirming our previous findings. In N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine pretreated rats, the inhibitory effect of UK-14304 on acetylcholine outflow persisted, while the ability of (+)-efaroxan to increase outflow was essentially eliminated. In locus coeruleus-lesioned rats, where cortical noradrenaline levels were reduced by 64%, (+)-efaroxan still increased acetylcholine outflow, but this effect was significantly attenuated and less sustained in comparison to sham-operated control rats. Viewed together with complimentary biochemical, electrophysiological and neuroanatomical evidence in the literature, a model is presented to account for these findings, and indicates that alpha2-adrenoceptors both on noradrenergic neurons (autoreceptors) and on non-noradrenergic cells (heteroreceptors) can participate in mediating drug-induced changes in medial prefrontal cortical acetylcholine release in vivo. The acetylcholine release-enhancing effect of (+)-efaroxan appears to be dependent on at least a partially intact cortical noradrenergic innervation.
Assuntos
Acetilcolina/metabolismo , Agonistas alfa-Adrenérgicos/farmacologia , Antagonistas Adrenérgicos alfa/farmacologia , Benzofuranos/farmacologia , Córtex Cerebral/metabolismo , Imidazóis/farmacologia , Quinoxalinas/farmacologia , Receptores Adrenérgicos alfa 2/fisiologia , Animais , Anti-Hipertensivos/farmacologia , Benzilaminas/farmacologia , Tartarato de Brimonidina , Cerebelo/efeitos dos fármacos , Cerebelo/metabolismo , Córtex Cerebral/efeitos dos fármacos , Epinefrina/metabolismo , Globo Pálido/efeitos dos fármacos , Globo Pálido/metabolismo , Técnicas In Vitro , Cinética , Lobo Parietal/efeitos dos fármacos , Lobo Parietal/metabolismo , Córtex Pré-Frontal/efeitos dos fármacos , Córtex Pré-Frontal/metabolismo , Ratos , Substância Inominada/efeitos dos fármacos , Substância Inominada/metabolismo , Simpatomiméticos/farmacologiaRESUMO
Six pairs of female squirrel monkeys were given a daily intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 9-14 days, beginning the same day on which they received either a bilateral 6-hydroxydopamine lesion or a sham lesion of the locus coeruleus. Sham animals developed typical parkinsonian signs (i.e. tremor, bradykinesia, hypokinesia and reduced blink rate) which largely recovered by six to nine weeks after the start of MPTP treatment. At nine weeks, post mortem levels of striatal dopamine in these same animals were partially reduced (by 45%), and this only in the putamen, compared to values obtained from three non-operated, normal control animals. Additionally, histological examination revealed a moderate loss of neuronal cell bodies in the substantia nigra, pars compacta. In marked contrast, the locus coeruleus-lesioned monkeys exhibited little or no recovery from the parkinsonian signs induced by MPTP. Post mortem examination of these animals revealed profound decreases in caudate (by 84%) and putamen (by 91%) dopamine content, and severe neuronal cell loss in the substantia nigra pars compacta of all animals. These neurological, biochemical and histological assessments indicate that lesioning of the locus coeruleus impairs the recovery which usually occurs from the parkinsonian manifestations induced by MPTP in squirrel monkeys. The results support the hypothesis that deficient locus coeruleus noradrenergic mechanisms underlie the progression of Parkinson's disease.
Assuntos
Corpo Estriado/fisiologia , Dopamina/metabolismo , Locus Cerúleo/fisiopatologia , Atividade Motora , Neurônios/fisiologia , Doença de Parkinson Secundária/fisiopatologia , Substância Negra/patologia , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina , Estimulação Acústica , Animais , Corpo Estriado/patologia , Eletrofisiologia/métodos , Feminino , Locomoção , Locus Cerúleo/patologia , Locus Cerúleo/fisiologia , Doença de Parkinson Secundária/induzido quimicamente , Doença de Parkinson Secundária/patologia , Estimulação Física , Valores de Referência , Saimiri , Tremor/fisiopatologiaRESUMO
It has been hypothesized [Colpaert, F.C., 1994. In: Briley, M., Marien, M. (Eds.), Noradrenergic Mechanisms in Parkinson's Disease. CRC Press, Boca Raton, FL, pp. 225-254] that a deficiency in the noradrenergic system originating from the locus coeruleus is a decisive factor in the progression of central neurodegenerative disorders including Alzheimer's disease, and that treatments which boost noradrenergic transmission (e.g. via blockade of alpha(2)-adrenoceptors) could provide both symptomatic and trophic benefits against the disease. Studies in the rat in vivo demonstrating that the selective alpha(2)-adrenoceptor antagonist dexefaroxan increases acetylcholine release in the cortex, improves measures of cognitive performance and protects against excitotoxin lesions, support this concept. As a further test of the hypothesis, we investigated the effect of dexefaroxan in a rat model of unilateral cortical devascularization that induces a loss of the cortical cholinergic terminal network and a retrograde degeneration of the cholinergic projections that originate in the nucleus basalis magnocellularis. Lesioned and sham-operated rats received a 28-day subcutaneous infusion of dexefaroxan (0.63 mg/rat/day) or vehicle, delivered by osmotic minipumps implanted on the day of the cortical devascularization procedure. In lesioned rats, the dexefaroxan treatment was associated with a significantly higher number and size of vesicular acetylcholine transporter-immunoreactive boutons in comparison to the vehicle treatment; this effect was most marked within cortical layer V. Dexefaroxan also significantly reduced the atrophy of cholinergic neurons within the nucleus basalis magnocellularis. Dexefaroxan had no observable effect on any of these parameters in sham-operated cohorts. These results show that systemically administered dexefaroxan mitigates cholinergic neuronal degeneration in vivo, and provide further evidence for a therapeutic potential of the drug in neurodegenerative diseases such as Alzheimer's disease, where central cholinergic function is progressively compromised.
Assuntos
Antagonistas de Receptores Adrenérgicos alfa 2 , Núcleo Basal de Meynert/efeitos dos fármacos , Benzopiranos/uso terapêutico , Fibras Colinérgicas/efeitos dos fármacos , Imidazóis/uso terapêutico , Degeneração Neural/tratamento farmacológico , Córtex Somatossensorial/efeitos dos fármacos , Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos alfa/uso terapêutico , Animais , Núcleo Basal de Meynert/química , Núcleo Basal de Meynert/patologia , Benzopiranos/farmacologia , Fibras Colinérgicas/química , Fibras Colinérgicas/patologia , Imidazóis/farmacologia , Masculino , Degeneração Neural/patologia , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/uso terapêutico , Ratos , Ratos Sprague-Dawley , Receptores Adrenérgicos alfa 2/fisiologia , Córtex Somatossensorial/irrigação sanguínea , Córtex Somatossensorial/fisiologiaRESUMO
A dysfunction of noradrenergic mechanisms originating in the locus coeruleus has been hypothesised to be the critical factor underlying the evolution of central neurodegenerative diseases [Colpaert FC (1994) Noradrenergic mechanism Parkinson's disease: a theory. In: Noradrenergic mechanisms in Parkinson's disease (Briley M, Marien M, eds) pp 225-254. Boca Raton, FL, USA: CRC Press Inc.]. alpha(2)-Adrenoceptor antagonists, presumably in part by facilitating central noradrenergic transmission, afford neuroprotection in vivo in models of cerebral ischaemia, excitotoxicity and devascularization-induced neurodegeneration. The present study utilised the rat olfactory bulb as a model system for examining the effects of the selective alpha(2)-adrenoceptor antagonist dexefaroxan upon determinants of neurogenesis (proliferation, survival and death) in the adult brain in vivo. Cell proliferation (5-bromo-2'-deoxyuridine labelling) and cell death associated with DNA fragmentation (terminal dideoxynucleotidyl transferase-catalysed 2'-deoxyuridine-5'-triphosphate nick end-labelling assay) were quantified following a 7-day treatment with either vehicle or dexefaroxan (0.63 mg/kg i.p., three times daily), followed by a 3-day washout period. The number of terminal dideoxynucleotidyl transferase-catalysed 2'-deoxyuridine-5'-triphosphate nick end-labelling-positive nuclei in the olfactory bulb was lower in dexefaroxan-treated rats, this difference being greatest and significant in the subependymal layer (-52%). In contrast, 5-bromo-2'-deoxyuridine-immunoreactive nuclei were more numerous (+68%) in the bulbs of dexefaroxan-treated rats whilst no differences were detected in the proliferating region of the subventricular zone. Terminal dideoxynucleotidyl transferase-catalysed 2'-deoxyuridine-5'-triphosphate nick end-labelling combination with glial fibrillary acidic protein or neuronal-specific antigen immunohistochemistry revealed that terminal dideoxynucleotidyl transferase-catalysed 2'-deoxyuridine-5'-triphosphate nick end-labelling-positive nuclei were associated primarily with a neuronal cell phenotype. These findings suggest that dexefaroxan increases neuron survival in the olfactory bulb of the adult rat in vivo, putatively as a result of reducing the apoptotic fate of telencephalic stem cell progenies.
Assuntos
Antagonistas de Receptores Adrenérgicos alfa 2 , Antagonistas Adrenérgicos alfa/farmacologia , Benzopiranos/farmacologia , Imidazóis/farmacologia , Neurônios/efeitos dos fármacos , Bulbo Olfatório/efeitos dos fármacos , Animais , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Masculino , Neurônios/citologia , Neurônios/fisiologia , Fármacos Neuroprotetores/farmacologia , Bulbo Olfatório/citologia , Bulbo Olfatório/fisiologia , Ratos , Ratos Sprague-Dawley , Receptores Adrenérgicos alfa 2/fisiologiaRESUMO
The present study examined the effect of a selective delta-opioid receptor agonist [D-Ala2-D-Leu5] enkephalin (DADL) on the spontaneous and the L-glutamic acid (L-Glu)-evoked release of endogenous dopamine from superfused slices of rat caudate-putamen. The amount of dopamine in slice superfusates was measured by a sensitive method employing high-performance liquid chromatography with electrochemical detection (h.p.l.c.-e.d.) after a two-step separation procedure. The spontaneous release of endogenous dopamine was partially dependent on Ca2+, enhanced in Mg2+-free superfusion medium, partially reduced by tetrodotoxin (TTX, 0.3 microM), partially reduced by the putative excitatory amino acid receptor antagonist DL-2-amino-7-phosphonoheptanoic acid (DL-APH, 1 mM), and increased 10 fold by the dopamine uptake blocker, nomifensine (10 microM). DADL (5 and 50 nM) did not significantly affect spontaneous dopamine release. L-Glu (0.1-10 mM) produced a concentration-dependent release of endogenous dopamine from slices of caudate-putamen. This effect was Ca2+-dependent, strongly inhibited by 1.2 mM Mg2+, attenuated by DL-APH (1 mM), attenuated by TTX (0.3 microM), and enhanced by nomifensine (10 microM). In the presence of nomifensine DADL (50 nM) reduced significantly the L-Glu-evoked release of endogenous dopamine by 20%. The inhibitory effect of DADL was blocked by 10 microM naloxone. These results indicate that L-Glu stimulates the Ca2+-dependent release of endogenous dopamine in the caudate-putamen by activation of N-methy-D-aspartate-type of excitatory amino acid receptors. This release can be selectively modified by the delta-opioid agonist DADL in a naloxone-sensitive manner.